# Regorafenib Post-marketing Surveillance

> **NCT01843400** · — · COMPLETED · sponsor: **Bayer** · enrollment: 1301 (actual)

## Conditions studied

- Colorectal Neoplasms

## Interventions

- **DRUG:** Regorafenib (Stivarga, BAY73-4506)

## Key facts

- **NCT ID:** NCT01843400
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04-22
- **Primary completion:** 2016-09-12
- **Final completion:** 2016-11-14
- **Target enrollment:** 1301 (ACTUAL)
- **Last updated:** 2018-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01843400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01843400, "Regorafenib Post-marketing Surveillance". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01843400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*